pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-100 |
Genomic Coordinates | chr11: 122152229 - 122152308 |
Synonyms | MIRN100, miR-100, MIR100 |
Description | Homo sapiens miR-100 stem-loop |
Comment | This sequence is localised to chromosome 11 and was named mir-100-11 in reference . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-100-3p | |||||||||||||||||||||||||||
Sequence | 48| CAAGCUUGUAUCUAUAGGUAUG |69 | |||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||
Experiments | Cloned | |||||||||||||||||||||||||||
Editing Events in miRNAs |
|
|||||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | C16orf87 | ||||||||||||||||||||
Synonyms | - | ||||||||||||||||||||
Description | chromosome 16 open reading frame 87 | ||||||||||||||||||||
Transcript | NM_001001436 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on C16orf87 | |||||||||||||||||||||
3'UTR of C16orf87 (miRNA target sites are highlighted) |
>C16orf87|NM_001001436|3'UTR 1 TACTTGTTTGCAAAATCTGCTGAAACTTCTGTCAGGATAACATCAGCAAATTCTCAAACAGTTATGGACTCTCAGGAGCA 81 TTCTGACTGCATCAATAAGGGCCATCGATTGTTTCTTTCTCGCCTGTCGTTTAGCCTGTGCCACACTTCGGGAGCAAAGC 161 TGTGTAGGCTTGGACTGTTCTGGGATTTCCTTGTTTACCAAGGAGTATTGTCAGTGTTTTGTGTTTGGGATATAAGTAAG 241 TGTATTTGCCAACAACAAAAAAAAACCAACAAAAATGCTGGATGGATGTTAAAGGATAAAAAGTGATGGGGTATGGGGTA 321 GGTATGAAAACTAGGGTAATAAGATGCTTGATTGTTTTCAGGTTTGCCACCAGAGATGCAATATTTTAAATACTGTCAGA 401 AAGAGTGATTTTTAAAAATATATATTTCAGATTTTCAGTGCTAACAGATTGCATATATACAGTTCATTTACTTTTATTAA 481 ATTGGCAATCGATATTTTATTGAATGGGGAATTAAGAATATAAACTGTAAATTTTGTCTTAAATTGATTTTTTTTCTTGG 561 CCTTTATTTTTATTACTTAAGGTATGAGTTATATTTTAGGAGATACTTTCTAGACAGTTTGAAGTTTGGGTGCTATATGA 641 AGAAAAACATTTAATGATATACTCAGATATAAACACCTTGTTTTCTTGAATGTAATTTATTTATTAGCTAAAAAAAAAAA 721 ACAAACTGCTCTCAAGATGGTGCCTGTTAACCTAAACATGAAATATATTTATTACATGCAAAATATTTCTTAGCCACTTT 801 TAAGCAGTAATGTTTTATCTGAATGGATATTTGTTTCTATATCCTGATAATTATTTAAATTGTTACTTTCAATCTGGAAG 881 AAAAAATAAACCTTAATATTGAAACTAAGTAGATTAAATAGTGTGATAAAAGTTTTTTGTTCTGGTGAAGTTTGTGAAAT 961 ATATTTAAATTCTTAATTTTTCTAGTGTTAAGTCATAATCGTTTATAGTTGATTTATATTAAATGCTTTTGCATTTTGGC 1041 ATATCAATTTAATGATTAACATATTCAAACTTGGTAATCACTCCCCTTATTTTCAGTCGCTCTTCCCCCAATCTGTTTAG 1121 AAATCCTTTTAAAGCCTTCTTACAGAAGATAGTCATCAGTTAGATTTAGCCCCCTTTTAAGAGAATCTCCCTTTCAATTT 1201 TAGCCGTAACATTATCAATTTCAGACTTCATCCTGCATCTCCCATCACCTCCTCAAAGAAAAAAGGTCAACATTTTTTCC 1281 TACTTTATTTAAATGGTAACCAGCAGAGGGAGCTTAAGAGGTACTCTAGATAGGATAAAGAATTTTCCTAAGGATTCCTT 1361 TTCCTTTAATCCCTGTATCTATCTGCAGGTACTACTGCAACTATTTTGTATGCATTTTATTTATTTATTTAGGAGACAGA 1441 GTCTTGCTCGGTCGCCCAGGCTGGAGTGCAGTGGCACTGTCTCAGCTCACTGCAACCTCTGCCTCCTGGGTTCAAGTGAT 1521 TCTTATGCCTCAGCCTCCTGAGTAGCTGTGACTAGAGGCGTGCGCCACCACGCCTGGCTGTTTTTTTTTTTGTATTTTTT 1601 AGTACAGATGGGGTCTCAGCATGTTGGCCAGGCTGGTCTCAAATTCCTGGCCTTAGGTGATCTGCCCGCCTTGGCCTCCC 1681 AAAGTGCTGGGATTACAGGCATGAGCCACTGCACTCAGCCTTGTGTGCGTTTTAGAGTCTTAACTAGTAGTTTCCCCAAT 1761 AATGTAATGTGATTTTATCTTTGAAACATACTGTAAGGAAACTTTTGATTTTAAGTAAAAAAGCTTAAAAATGATTAATA 1841 TCTAAAAATGCTTGTATACATATATATGTCCTCAGAAAAAGCAAGAACAGCTTGTGGAATAAGCACGTCTTTAAGGAATT 1921 ATCGATGTCAGAGTCTATCCATTTAAAGCTGAAGACCATTACAGGAAAGTCATGTTAAAATATTCATTGGATATGGTAAA 2001 GGAGGTACTGGTGGCTGGGCTGGAGCTTGCCGTATAGAAAAGTAATTACTTCAGATCTCATAATGTTAAATTATTGGCTT 2081 ATTTAAAAATTTCCGTGGCAGAGAGGCAAATTAGGTTTCCTCTGTGACATAACCTATTTAACCAATTTTTCAAAAAATTG 2161 TACTCTATGAGCTTTCTTGTTATAAAGCTAAAAAATTTAATTTGTCTAGGCATGTTGTAATGGTCCCAGAAAATATTACT 2241 TTGTCACTGGTGTCAGAGAAACCTCTGTCATCAGCAGATGTCCTAAGAGTATAATTATAGTTCTTTACTTAATCCAAAAT 2321 TTGTTCTGCTCTGATATCTATAAATGATATGATTATTCAAAATACCTTGAAATGATTCCACAATTAGATTAGGTCTGTTG 2401 AAGATAACTTATTCTTAAATATGAGTAAGATTAAATAAAAGTAGTTTGAGAGTTGTTACTCCCTGCCTCAACTCCATGGT 2481 ATTCCAAAATGTTTTTGTGGGCACTTTAATACTTGTAGTTTGATTTTGTTTGTTAGTTTTAGAAATGAACATTTCTTAGA 2561 TTTTCATGGGTATTTTTTGGCTGTATTTAAATGTAAATGATATAAAAGTAAGGGAAATTGTGCAAATTATTTCTTGTGTA 2641 GTAATCAGTGGAAGTGATCAAACAGCTTGAAGCAGTTTATGATGAGAAAATTTAAAATTGCAAATGACCTGAAAATTTAG 2721 CCAGTCTATTCTTATTTCTTTAAATTTCAGAAATACTTAAGAAAAAAAAAAAAAAGGTCAGTATGACCTCTGAGTTGCTT 2801 CCTAAAAGTAATCAGATAGTGTTCTCCCTCAGATAAGATTTCAAATTGAAAAGTATTTGACTTCTTTAACTCTAGTAATT 2881 GCACTTGATTCTCTAATTCTGATCATTAAAATGACTTGGCAATATTTAATTTTGGCTTGCCTTTCAATCTGCATGTTTGT 2961 CTTAAATTTAGAAAAATTAAGCTCTTTACTTACTTTTATATAAAGTATTAATTGGCCAGGCATGGTGGCTTACACCTGTA 3041 ATCCCAACACTTTGGGAGGCCAAGGCAGGAGAGTTGTTTGAAGCCAGGAGTTTGAGACCAGCCTGGGCAACATGATGAGA 3121 CCGCGTCTCTACAAAAAGTAAAATTAGCTGGGTGTGGTGCTTCCAGCTACTAGGCAGCTGAGGCTAAAGGATCACTTGAG 3201 CCCAGGAGTTCGAGGCTGCAGTGAGTGATGATCTTGCCACTGCACTCCAGCCTGGGAGGCAGAGCAAGAAACACCCTGTG 3281 TGAAAAAAGTATTGAATTTGTTTGATTCCACTTTCAAAATATGCTCTAGATACAGGTAGTCATTCTGCCAAATTGTGTTC 3361 TTCTCTAAAACATTTTGTCCGTCATTCTTTGAAACTCATTCTTAATTATTTCCACTTTACCTTCTAGTTTGGTTTGATGC 3441 CTTATATTCTTGCTAGTTAAAAGCATTTTTTCCCTAGTATTTTCTGTCTTTCTAGCCTTTAAGGCATATTGTTGTTAACA 3521 AATCTCTTATTTAAGTTAATTAAAGTTTTTTCTGTGCAGCTGGGTTTTTTCTTTTACTACATGACAAGCTTCATTTTTAC 3601 ATTTGGAAGTACATGTATATATGTTTATATATTTTTATTCTCAGGATCTATTTTCTAGGGAACTATTTTTTTAAATTATT 3681 CTTTTGTGCTGCCTTAACCCATTTATTATAGTTTGAATATTAGTAGTACTTACTACTCAAAGATTACAACTATACTAATA 3761 ACTATCCTAACATACAAAGCAGACTCTCCAGGATTAAAAGTATGAGACATATAACAGAGTCTGGAATAGAATAATTCTTT 3841 TTACCCCAGTCAAGTATTTGCCTTTTGCATTATTAAGGAATCTGTTTTGTTCTTTTATTGATAATTTCTATATTTTTTTC 3921 TTTGCCTTATTGCACTGGTTGGGACTTTTTGCCTTGATCCAGTTGTAGGGGGGAAACATTCAGTCATTAAGCATTAAATA 4001 ACTTTGTTGTTGTTGTGGGCTTGAAAAAATACCCTTTAGTAGATTGAGGGTAGACTCTTTTATTTCTGCTTGTTGGAAGT 4081 TTTCTGTCAGGAACAGATGTTGAATTTTGTCAGATGCTTTTTCTGCATAATTGATAGGACCTTTTTTCTCCCCTTTAGAA 4161 TGTTCATATGGTGAAACATACTGATAGCTTTTCTTTTCTTTTTTTTTTGACACGGAGTCTCACTCTGTCACCCAGGCTGG 4241 AGTGCAATGGTGCGATCTTGGCTCACTGCACCCTCTGCCTCTTGGGTTCAAGCTTCCCTCACCAGCCTCCCAAGTACCTG 4321 GGTATACAGGTGTGCATCACCATGCCCGGCTAATTTTTGAATTTTTAGTAGAGATAGGTTTTTACCATGTTGGCCAGGCT 4401 GGTCTTCAACTCCTGACTCAGCCTCCCAAAGTGTTGGGATTACAGTCTCGCTCTGTCGCCCAGGCTGGAGGGCAGTGGTG 4481 TGATCTTGGCTCAATGCAACCTTGCAACCTCTGCCTCCCGAGTTCAAGCGATTCTCCTGCCTTAGCCTCCTGAGTAGCTG 4561 GAATTACAGGCGCACGCCACTACACCCAGCTTCTTTTTGTATTTTTAGTAGAGATGGAGTTTCACCATGTTGGCCAAGCT 4641 GGTCTCGAACTCCTGAGCTCCGGTGATCCACCCGCCTTTACAGGCATGAGCCACCGTGCCCGGCTGCATTTCTCTTTTGT 4721 AAGAACCTGCTCTGGTTTATTGATATTTTGCTGTTTTTCTGTTTTAAGTTTCATTAATTTCTGATCTTTAGTATTTTCTC 4801 CTTTCTTTGCTTTGGGCTTATTTGCTCCCTTTTCTAGCTTATTGTGGCGGAAGCTCAGATCATTGATTTTAAAATTTACT 4881 TATTTATTTATTTATTTATTTAATTCAACACTGATCAGAAGGCTTTTTGTGCTTTTCTAAAAAAAGCATTTAATGCTATA 4961 AATTTCCCATTTGCTTTATCTCACAAATTTTATTGTGTTGTAATTTTGTGTTCAATTTAGAATATTCTGATTTTTCTTGG 5041 TATTACTATAATTTTCAAATATTTAGAGTTTTTTTCAGTTATCTTTCTGTTACTGATTGTAATTTATTGTTTTTTAAAAT 5121 TATAGTTCTTTGAATAGTTTTGCAGTATTTGCTCTAGGGATTACTATAAACATACTTCACTTTTTACAGTTCACTTAGAA 5201 GTCAATATTTTACCAGTTCAAGTGGAATGTAGAAAAATCTTACCACTGTTTACATTCCTTTACCCTCTCCCCTTTATGTT 5281 ATAATTTTCTTATAAATCATAAGACTTGGCTGGGCACAGTGGCTCACCTGTAATCCCAGGACTGGGAGGCCGAGGCGAGC 5361 AGATTGCTTAAGTCCAGGAGTTCGAGACCAGCCTGGACAATGTGGTGAAACCCCAACTCTACAAAAAATACACAAAATTA 5441 GCTAGGCGTGGTAGCATGTTCCTGTAGTCCCAGCTACTCAGGAGGCTGAAGTGGGAGGATTACTTGAGCCCAGGAGGCAG 5521 AGGTTGCAGTGAGCCAAGATCACTCCACTCCACTCCAGCCTGAGTGACAGAGCTAGACACTGTGTCTCAAAAAATAAAAA 5601 TAAAAAATAAGACTCATCAGATAATGTATTTTTTCCTTACAACTATCATAGATATTTTTAAGAACCCAAGAGGAAAACAG 5681 TCTATCACATTTACCACAATATTTATCATTTGTATTAATCTTCCTTAATTCTTGATGTTCCAAGTTTACATAGGTATCAG 5761 TCCTTTTCATCTGGAAAATTTCTTTTAGTGCAGGTCTGTTGACATTTAATTCTCTTATTTTTTCTTCATCTGAGAATGTC 5841 TTTATTTTGCCTTAATTCATGAAAGATATTTTTGCTGGATATAAACTACTGTGTTGACAGTTCTTTCAGCCTCCATGGTT 5921 TCTGATGAGAAATGTGCAGCCATTAAAGTAATATTTCCCCTGTATGAAACATGTTATTTTTCTCTGAGTATTTTCAGGAA 6001 TCTTTGTCTTTGGTTTTTATTGGTTTGATTATGATGTGCCCGGGTGTTTGAATTTATTCTCTTTGGGATTTGTTGAGCTT 6081 AAATGTGTAAGTTTATGCCTTTCATCAGATTATGTAAAGTTTTAAACCATTCAGATATTTTCTGCTCTACTTTCTCCTCC 6161 CTCTTAGGCTCCAGTGATGCAAGTGTTAGACTCTTTGGTATTATCTCACAGATCTCAGAACCTCTGTTCATTTATTTTAT 6241 TTTAATAAATCATTTCAGTTAACAAAATCATATATTGTATGCAGCATGATGTTTCAATATGTATGTTCACATTGTAGGAT 6321 GTCTAAAGTAAAGATAATGAACATAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | BC-1 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM796038. RNA binding protein: AGO2. Condition:4-Thiouridine
... - Gottwein E; Corcoran DL; Mukherjee N; et al., 2011, Cell host & microbe. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Gottwein E; Corcoran DL; Mukherjee N; et al. - Cell host & microbe, 2011
Primary effusion lymphoma (PEL) is caused by Kaposi's sarcoma-associated herpesvirus (KSHV) and frequently also harbors Epstein-Barr virus (EBV). The expression of KSHV- and EBV-encoded microRNAs (miRNAs) in PELs suggests a role for these miRNAs in latency and lymphomagenesis. Using PAR-CLIP, a technology which allows the direct and transcriptome-wide identification of miRNA targets, we delineate the target sites for all viral and cellular miRNAs expressed in PEL cell lines. The resulting data set revealed that KSHV miRNAs directly target more than 2000 cellular mRNAs, including many involved in pathways relevant to KSHV pathogenesis. Moreover, 58% of these mRNAs are also targeted by EBV miRNAs, via distinct binding sites. In addition to a known viral analog of cellular miR-155, we show that KSHV encodes a viral miRNA that mimics cellular miR-142-3p function. In summary, this study identifies an extensive list of KSHV miRNA targets, which are likely to influence viral replication and pathogenesis.
LinkOut: [PMID: 22100165]
|
CLIP-seq Support 1 for dataset GSM796038 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | BC-1 / 4-Thiouridine |
Location of target site | ENST00000394806.2 | 3UTR | UCAAGCUUCCCUCACCA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22100165 / GSE32109 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
107 hsa-miR-100-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT105690 | LEPROTL1 | leptin receptor overlapping transcript like 1 | 2 | 2 | ||||||||
MIRT151558 | HNRNPUL1 | heterogeneous nuclear ribonucleoprotein U like 1 | 2 | 4 | ||||||||
MIRT167753 | SGK1 | serum/glucocorticoid regulated kinase 1 | 2 | 2 | ||||||||
MIRT195380 | CBFB | core-binding factor beta subunit | 2 | 2 | ||||||||
MIRT283995 | DNAJA2 | DnaJ heat shock protein family (Hsp40) member A2 | 2 | 2 | ||||||||
MIRT317145 | E2F3 | E2F transcription factor 3 | 2 | 4 | ||||||||
MIRT380785 | ZFP3 | ZFP3 zinc finger protein | 2 | 2 | ||||||||
MIRT380927 | ZNF264 | zinc finger protein 264 | 2 | 2 | ||||||||
MIRT441600 | ABCB5 | ATP binding cassette subfamily B member 5 | 2 | 6 | ||||||||
MIRT443896 | NUDT3 | nudix hydrolase 3 | 2 | 4 | ||||||||
MIRT444030 | GREM1 | gremlin 1, DAN family BMP antagonist | 2 | 4 | ||||||||
MIRT444112 | CEPT1 | choline/ethanolamine phosphotransferase 1 | 2 | 2 | ||||||||
MIRT444169 | ZNF701 | zinc finger protein 701 | 2 | 2 | ||||||||
MIRT444366 | TIMM8B | translocase of inner mitochondrial membrane 8 homolog B | 2 | 2 | ||||||||
MIRT444371 | CNBP | CCHC-type zinc finger nucleic acid binding protein | 2 | 2 | ||||||||
MIRT444517 | ZNF525 | zinc finger protein 525 | 2 | 2 | ||||||||
MIRT444525 | CNIH4 | cornichon family AMPA receptor auxiliary protein 4 | 2 | 2 | ||||||||
MIRT444529 | EIF2A | eukaryotic translation initiation factor 2A | 2 | 2 | ||||||||
MIRT444537 | PHKB | phosphorylase kinase regulatory subunit beta | 2 | 2 | ||||||||
MIRT444702 | GATSL2 | cytosolic arginine sensor for mTORC1 subunit 2 | 2 | 2 | ||||||||
MIRT444717 | CMSS1 | cms1 ribosomal small subunit homolog (yeast) | 2 | 2 | ||||||||
MIRT444730 | TMC7 | transmembrane channel like 7 | 2 | 2 | ||||||||
MIRT444777 | NAPEPLD | N-acyl phosphatidylethanolamine phospholipase D | 2 | 2 | ||||||||
MIRT444802 | TMEM251 | transmembrane protein 251 | 2 | 2 | ||||||||
MIRT444995 | LRRC57 | leucine rich repeat containing 57 | 2 | 2 | ||||||||
MIRT445073 | C16orf87 | chromosome 16 open reading frame 87 | 2 | 2 | ||||||||
MIRT445250 | SEMA5A | semaphorin 5A | 2 | 2 | ||||||||
MIRT445336 | KATNAL1 | katanin catalytic subunit A1 like 1 | 2 | 2 | ||||||||
MIRT445426 | TPT1 | tumor protein, translationally-controlled 1 | 2 | 4 | ||||||||
MIRT445469 | TRIM13 | tripartite motif containing 13 | 2 | 2 | ||||||||
MIRT445646 | NPY4R | neuropeptide Y receptor Y4 | 2 | 2 | ||||||||
MIRT445759 | AGO1 | argonaute 1, RISC catalytic component | 2 | 2 | ||||||||
MIRT445838 | SRSF11 | serine and arginine rich splicing factor 11 | 2 | 2 | ||||||||
MIRT445868 | ENTPD7 | ectonucleoside triphosphate diphosphohydrolase 7 | 2 | 2 | ||||||||
MIRT446368 | STX16 | syntaxin 16 | 2 | 2 | ||||||||
MIRT446444 | THYN1 | thymocyte nuclear protein 1 | 2 | 2 | ||||||||
MIRT446593 | TASP1 | taspase 1 | 2 | 2 | ||||||||
MIRT446926 | SRSF7 | serine and arginine rich splicing factor 7 | 2 | 2 | ||||||||
MIRT447121 | SLFN5 | schlafen family member 5 | 2 | 2 | ||||||||
MIRT447196 | CDCP1 | CUB domain containing protein 1 | 2 | 2 | ||||||||
MIRT447358 | STOM | stomatin | 2 | 2 | ||||||||
MIRT447361 | FAM161B | family with sequence similarity 161 member B | 2 | 2 | ||||||||
MIRT447374 | NUP205 | nucleoporin 205 | 2 | 2 | ||||||||
MIRT447467 | OSMR | oncostatin M receptor | 2 | 2 | ||||||||
MIRT447606 | MRPL3 | mitochondrial ribosomal protein L3 | 2 | 2 | ||||||||
MIRT447682 | ASPA | aspartoacylase | 2 | 2 | ||||||||
MIRT447715 | ERP44 | endoplasmic reticulum protein 44 | 2 | 2 | ||||||||
MIRT447814 | EMX1 | empty spiracles homeobox 1 | 2 | 2 | ||||||||
MIRT447855 | RRP8 | ribosomal RNA processing 8 | 2 | 4 | ||||||||
MIRT447866 | KIAA1244 | ARFGEF family member 3 | 1 | 1 | ||||||||
MIRT447890 | STRIP2 | striatin interacting protein 2 | 2 | 2 | ||||||||
MIRT447916 | PACSIN1 | protein kinase C and casein kinase substrate in neurons 1 | 2 | 2 | ||||||||
MIRT447935 | DUSP4 | dual specificity phosphatase 4 | 2 | 2 | ||||||||
MIRT448813 | GABRB1 | gamma-aminobutyric acid type A receptor beta1 subunit | 2 | 2 | ||||||||
MIRT448927 | CKS1B | CDC28 protein kinase regulatory subunit 1B | 2 | 2 | ||||||||
MIRT449105 | CREBRF | CREB3 regulatory factor | 2 | 2 | ||||||||
MIRT449216 | ZNHIT3 | zinc finger HIT-type containing 3 | 2 | 2 | ||||||||
MIRT449336 | ACTBL2 | actin, beta like 2 | 2 | 2 | ||||||||
MIRT449675 | SOX3 | SRY-box 3 | 2 | 2 | ||||||||
MIRT449724 | POU2F1 | POU class 2 homeobox 1 | 2 | 2 | ||||||||
MIRT449768 | PRAMEF7 | PRAME family member 7 | 2 | 2 | ||||||||
MIRT449804 | PRAMEF8 | PRAME family member 8 | 2 | 2 | ||||||||
MIRT449850 | BCL2L13 | BCL2 like 13 | 2 | 2 | ||||||||
MIRT449866 | POFUT2 | protein O-fucosyltransferase 2 | 2 | 2 | ||||||||
MIRT450067 | SYT9 | synaptotagmin 9 | 2 | 2 | ||||||||
MIRT450197 | ZHX3 | zinc fingers and homeoboxes 3 | 2 | 2 | ||||||||
MIRT450386 | TENM4 | teneurin transmembrane protein 4 | 2 | 2 | ||||||||
MIRT450435 | PAX8 | paired box 8 | 2 | 2 | ||||||||
MIRT450716 | PVRL3 | nectin cell adhesion molecule 3 | 2 | 2 | ||||||||
MIRT495906 | PGM2L1 | phosphoglucomutase 2 like 1 | 2 | 2 | ||||||||
MIRT497543 | PPTC7 | PTC7 protein phosphatase homolog | 2 | 2 | ||||||||
MIRT497630 | ZNF576 | zinc finger protein 576 | 2 | 2 | ||||||||
MIRT497756 | OXGR1 | oxoglutarate receptor 1 | 2 | 2 | ||||||||
MIRT498072 | SLC25A12 | solute carrier family 25 member 12 | 2 | 2 | ||||||||
MIRT500542 | XPO4 | exportin 4 | 2 | 4 | ||||||||
MIRT500848 | SYPL1 | synaptophysin like 1 | 2 | 4 | ||||||||
MIRT511621 | HIST1H3J | histone cluster 1 H3 family member j | 2 | 4 | ||||||||
MIRT513745 | PKNOX1 | PBX/knotted 1 homeobox 1 | 2 | 2 | ||||||||
MIRT535077 | PPP1CB | protein phosphatase 1 catalytic subunit beta | 2 | 2 | ||||||||
MIRT543133 | ZFP36L1 | ZFP36 ring finger protein like 1 | 2 | 2 | ||||||||
MIRT544518 | GTF2E2 | general transcription factor IIE subunit 2 | 2 | 2 | ||||||||
MIRT544666 | MED19 | mediator complex subunit 19 | 2 | 2 | ||||||||
MIRT545407 | KIAA1715 | lunapark, ER junction formation factor | 2 | 2 | ||||||||
MIRT547569 | LRIG3 | leucine rich repeats and immunoglobulin like domains 3 | 2 | 4 | ||||||||
MIRT548767 | CNN3 | calponin 3 | 2 | 2 | ||||||||
MIRT551009 | TRIM4 | tripartite motif containing 4 | 2 | 2 | ||||||||
MIRT555077 | PURG | purine rich element binding protein G | 2 | 2 | ||||||||
MIRT560753 | ZNF616 | zinc finger protein 616 | 2 | 2 | ||||||||
MIRT563752 | FOXO3 | forkhead box O3 | 2 | 2 | ||||||||
MIRT565531 | SON | SON DNA binding protein | 2 | 2 | ||||||||
MIRT613933 | HIVEP3 | human immunodeficiency virus type I enhancer binding protein 3 | 2 | 2 | ||||||||
MIRT614433 | TAZ | tafazzin | 2 | 2 | ||||||||
MIRT622520 | RAP2A | RAP2A, member of RAS oncogene family | 2 | 2 | ||||||||
MIRT626037 | AREL1 | apoptosis resistant E3 ubiquitin protein ligase 1 | 2 | 2 | ||||||||
MIRT648459 | LEAP2 | liver enriched antimicrobial peptide 2 | 2 | 2 | ||||||||
MIRT654982 | PLCXD3 | phosphatidylinositol specific phospholipase C X domain containing 3 | 2 | 4 | ||||||||
MIRT689103 | ZBTB25 | zinc finger and BTB domain containing 25 | 2 | 2 | ||||||||
MIRT704259 | DHCR24 | 24-dehydrocholesterol reductase | 2 | 2 | ||||||||
MIRT711194 | CXCL3 | C-X-C motif chemokine ligand 3 | 2 | 2 | ||||||||
MIRT713315 | VLDLR | very low density lipoprotein receptor | 2 | 2 | ||||||||
MIRT717266 | BMPR2 | bone morphogenetic protein receptor type 2 | 4 | 2 | ||||||||
MIRT718248 | CCDC18 | coiled-coil domain containing 18 | 2 | 2 | ||||||||
MIRT721944 | NGRN | neugrin, neurite outgrowth associated | 2 | 2 | ||||||||
MIRT721948 | IL1RAPL1 | interleukin 1 receptor accessory protein like 1 | 2 | 2 | ||||||||
MIRT734969 | PIK3R1 | phosphoinositide-3-kinase regulatory subunit 1 | 3 | 0 | ||||||||
MIRT735945 | NME2 | NME/NM23 nucleoside diphosphate kinase 2 | 0 | 0 | ||||||||
MIRT737404 | HOXA1 | homeobox A1 | 4 | 0 |
miRNA-Drug Associations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|